Cargando…
The effect of sarcopenia and sarcopenic obesity on survival in gastric cancer
BACKGROUND: Sarcopenic obesity arises from increased muscle catabolism triggered by inflammation and inactivity. Its significance lies in its role in contributing to morbidity and mortality in gastric cancer. This study aims to explore the potential correlation between sarcopenia, sarcopenic obesity...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10537530/ https://www.ncbi.nlm.nih.gov/pubmed/37770828 http://dx.doi.org/10.1186/s12885-023-11423-y |
_version_ | 1785113124648517632 |
---|---|
author | Şahin, Muzaffer Ece Hakan Akbaş, Feray Yardimci, Aytul Hande Şahin, Eren |
author_facet | Şahin, Muzaffer Ece Hakan Akbaş, Feray Yardimci, Aytul Hande Şahin, Eren |
author_sort | Şahin, Muzaffer Ece Hakan |
collection | PubMed |
description | BACKGROUND: Sarcopenic obesity arises from increased muscle catabolism triggered by inflammation and inactivity. Its significance lies in its role in contributing to morbidity and mortality in gastric cancer. This study aims to explore the potential correlation between sarcopenia, sarcopenic obesity, and gastric cancer, as well as their effect on survival. MATERIALS AND METHODS: This retrospective study included 162 patients aged ≥ 18 years who were diagnosed with stomach cancer. Patient age, gender, diagnostic laboratory results, and cancer characteristics were documented. Sarcopenia was assessed using the skeletal muscle index (SMI) (cm2/m2), calculated by measuring muscle mass area from a cross-sectional image at the L3 vertebra level of computed tomography (CT). RESULTS: Among the 162 patients, 52.5% exhibited sarcopenia (with cut-off limits of 52.4 cm2/m2 for males and 38.5 cm2/m2 for females), and 4.9% showed sarcopenic obesity. Average skeletal muscle area (SMA) was 146.8 cm2; SMI was 50.6 cm2/m2 in men and 96.9 cm2 and 40.6 cm2/m2 in women, respectively. Sarcopenia significantly reduced mean survival (p = 0.033). There was no association between sarcopenic obesity and mortality (p > 0.05), but mortality was higher in sarcopenic obesity patients (p = 0.041). Patient weight acted as a protective factor against mortality, supporting the obesity paradox. Tumor characteristics, metabolic parameters, and concurrent comorbidities did not significantly impact sarcopenia or mortality. CONCLUSION: Sarcopenia is more prevalent in the elderly population and is linked to increased mortality in gastric cancer patients. Paradoxically, higher body mass index (BMI) was associated with improved survival. Computed tomography offers a practical and reliable method for measuring muscle mass and distinguishing these distinctions. TRIAL REGISTRATION: This study was approved by Istanbul Training and Research Hospital Clinical Research Ethics Committee of the University of Health Sciences (29.05.2020/2383). |
format | Online Article Text |
id | pubmed-10537530 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-105375302023-09-29 The effect of sarcopenia and sarcopenic obesity on survival in gastric cancer Şahin, Muzaffer Ece Hakan Akbaş, Feray Yardimci, Aytul Hande Şahin, Eren BMC Cancer Research BACKGROUND: Sarcopenic obesity arises from increased muscle catabolism triggered by inflammation and inactivity. Its significance lies in its role in contributing to morbidity and mortality in gastric cancer. This study aims to explore the potential correlation between sarcopenia, sarcopenic obesity, and gastric cancer, as well as their effect on survival. MATERIALS AND METHODS: This retrospective study included 162 patients aged ≥ 18 years who were diagnosed with stomach cancer. Patient age, gender, diagnostic laboratory results, and cancer characteristics were documented. Sarcopenia was assessed using the skeletal muscle index (SMI) (cm2/m2), calculated by measuring muscle mass area from a cross-sectional image at the L3 vertebra level of computed tomography (CT). RESULTS: Among the 162 patients, 52.5% exhibited sarcopenia (with cut-off limits of 52.4 cm2/m2 for males and 38.5 cm2/m2 for females), and 4.9% showed sarcopenic obesity. Average skeletal muscle area (SMA) was 146.8 cm2; SMI was 50.6 cm2/m2 in men and 96.9 cm2 and 40.6 cm2/m2 in women, respectively. Sarcopenia significantly reduced mean survival (p = 0.033). There was no association between sarcopenic obesity and mortality (p > 0.05), but mortality was higher in sarcopenic obesity patients (p = 0.041). Patient weight acted as a protective factor against mortality, supporting the obesity paradox. Tumor characteristics, metabolic parameters, and concurrent comorbidities did not significantly impact sarcopenia or mortality. CONCLUSION: Sarcopenia is more prevalent in the elderly population and is linked to increased mortality in gastric cancer patients. Paradoxically, higher body mass index (BMI) was associated with improved survival. Computed tomography offers a practical and reliable method for measuring muscle mass and distinguishing these distinctions. TRIAL REGISTRATION: This study was approved by Istanbul Training and Research Hospital Clinical Research Ethics Committee of the University of Health Sciences (29.05.2020/2383). BioMed Central 2023-09-28 /pmc/articles/PMC10537530/ /pubmed/37770828 http://dx.doi.org/10.1186/s12885-023-11423-y Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Şahin, Muzaffer Ece Hakan Akbaş, Feray Yardimci, Aytul Hande Şahin, Eren The effect of sarcopenia and sarcopenic obesity on survival in gastric cancer |
title | The effect of sarcopenia and sarcopenic obesity on survival in gastric cancer |
title_full | The effect of sarcopenia and sarcopenic obesity on survival in gastric cancer |
title_fullStr | The effect of sarcopenia and sarcopenic obesity on survival in gastric cancer |
title_full_unstemmed | The effect of sarcopenia and sarcopenic obesity on survival in gastric cancer |
title_short | The effect of sarcopenia and sarcopenic obesity on survival in gastric cancer |
title_sort | effect of sarcopenia and sarcopenic obesity on survival in gastric cancer |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10537530/ https://www.ncbi.nlm.nih.gov/pubmed/37770828 http://dx.doi.org/10.1186/s12885-023-11423-y |
work_keys_str_mv | AT sahinmuzafferecehakan theeffectofsarcopeniaandsarcopenicobesityonsurvivalingastriccancer AT akbasferay theeffectofsarcopeniaandsarcopenicobesityonsurvivalingastriccancer AT yardimciaytulhande theeffectofsarcopeniaandsarcopenicobesityonsurvivalingastriccancer AT sahineren theeffectofsarcopeniaandsarcopenicobesityonsurvivalingastriccancer AT sahinmuzafferecehakan effectofsarcopeniaandsarcopenicobesityonsurvivalingastriccancer AT akbasferay effectofsarcopeniaandsarcopenicobesityonsurvivalingastriccancer AT yardimciaytulhande effectofsarcopeniaandsarcopenicobesityonsurvivalingastriccancer AT sahineren effectofsarcopeniaandsarcopenicobesityonsurvivalingastriccancer |